Skip to main content

Table 4 Risk factor for all-cause mortality up to 60 days following allogeneic hematopoietic stem cell transplantation

From: Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital

Univariate analysis
 Pre-transplant factors Variables (Number) Mortality (%) P-value
  Gender Male (119) 19.3 0.13
Female (65) 10.8  
  Age ≥60 (80) 18.8 0.42
<60 (104) 14.4  
  Diagnosis Myeloid malignacy (119) 16.8 0.83
non Myeloid malignancy (65) 15.4  
  Diseases risk High risk hematological diseases (151) 19.2 0.028
Standard risk hematological diseases (33) 3.03  
  PH of allo-HSCT Yes (25) 32.0 0.017
No (159) 13.8  
  Donor typre CBT (135) 19.3 0.076
non CBT (49) 8.16  
  Conditioning RIC(63) 22.3 0.11
MAC (121) 13.2  
 Time dependent factors    
  Viridans streptococcal bacteremia VSB (28) 10.7 0.43
non VSB (156) 17.3  
  Engraftment within Day30 Yes (161) 9.94 <0.001
No (23) 60.9  
Multivariate analysis    
 Factors Hazard ratio 95 % confidence interval P-value
  High risk hematological diseases 5.59 0.741–42.18 0.095
  Prior history of allo-HSCT 2.09 0.919–4.740 0.079
  CBT 1.66 0.569–4.839 0.35
  Engraftment within Day30 0.22 0.087–0.558 0.0014
  1. CBT cord blood transplantation, RIC reduced-intensity conditioning, MAC Myeloablative conditioning, allo-HSCT allogeneic hematopoietic stem cell transplantation, VSB viridans streptococcal bacteremia, PH-allo-HSCT prior history of allogeneic hematopoietic stem cell transplantation